Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH) -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (55)	4/1/1998 3:54:00 PM
From: Biojunkie	Read Replies (2) \| Respond to of 138

The people on this thread continue to confuse people regarding the company,s lead product candidate as DHEA. PPB2 is an analog of a hormone and has been shown to be 10 times more potent than DHEA at inhibiting HIV Replication. In 1995 in a clinical trial by Dr. Salvato in Houston Texas DHEA was shown to inhibit HIV replication by 90% as a mono therapy. A Poster by this doctor was presented at the world aids conference in 1996. Stand corrected once again.